Niagen Bioscience (NAGE) Operating Leases (2019 - 2026)

Niagen Bioscience (NAGE) has 8 years of Operating Leases data on file, last reported at $1.5 million in Q1 2026.

• On a quarterly basis, Operating Leases fell 55.89% year-over-year to $1.5 million in Q1 2026; TTM through Mar 2026 was $1.5 million, a 55.89% decrease from a year earlier, with the FY2025 full-year figure at $1.8 million, down 30.19% from the prior year.
• Operating Leases for Q1 2026 stood at $1.5 million, down from $1.8 million in the prior quarter.
• Over the last five years, Operating Leases for NAGE reached as high as $4.5 million in Q2 2022 and fell as low as $1.5 million in Q1 2026.
• Historically, Operating Leases has averaged $3.1 million across 5 years, with a median of $3.1 million in 2023.
• Across the five-year window, Operating Leases soared 180.24% in 2022 and tumbled 55.89% in 2026, its largest moves.
• Year by year, Operating Leases stood at $3.5 million in 2022, then fell by 27.58% to $2.6 million in 2023, then rose by 1.44% to $2.6 million in 2024, then tumbled by 30.19% to $1.8 million in 2025, then declined by 14.93% to $1.5 million in 2026.
• Per Business Quant data, the three most recent Operating Leases figures were $1.5 million in Q1 2026, $1.8 million in Q4 2025, and $2.1 million in Q3 2025.